Cargando…
Brentuximab vedotin: targeting CD30 as standard in CTCL
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844715/ https://www.ncbi.nlm.nih.gov/pubmed/29552279 http://dx.doi.org/10.18632/oncotarget.24472 |
| _version_ | 1783305289592733696 |
|---|---|
| author | Prince, H. Miles Gautam, Ashish Kim, Youn H. |
| author_facet | Prince, H. Miles Gautam, Ashish Kim, Youn H. |
| author_sort | Prince, H. Miles |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5844715 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-58447152018-03-16 Brentuximab vedotin: targeting CD30 as standard in CTCL Prince, H. Miles Gautam, Ashish Kim, Youn H. Oncotarget Editorial Impact Journals LLC 2018-02-10 /pmc/articles/PMC5844715/ /pubmed/29552279 http://dx.doi.org/10.18632/oncotarget.24472 Text en Copyright: © 2018 Prince et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Editorial Prince, H. Miles Gautam, Ashish Kim, Youn H. Brentuximab vedotin: targeting CD30 as standard in CTCL |
| title | Brentuximab vedotin: targeting CD30 as standard in CTCL |
| title_full | Brentuximab vedotin: targeting CD30 as standard in CTCL |
| title_fullStr | Brentuximab vedotin: targeting CD30 as standard in CTCL |
| title_full_unstemmed | Brentuximab vedotin: targeting CD30 as standard in CTCL |
| title_short | Brentuximab vedotin: targeting CD30 as standard in CTCL |
| title_sort | brentuximab vedotin: targeting cd30 as standard in ctcl |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844715/ https://www.ncbi.nlm.nih.gov/pubmed/29552279 http://dx.doi.org/10.18632/oncotarget.24472 |
| work_keys_str_mv | AT princehmiles brentuximabvedotintargetingcd30asstandardinctcl AT gautamashish brentuximabvedotintargetingcd30asstandardinctcl AT kimyounh brentuximabvedotintargetingcd30asstandardinctcl |